Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 615

1.

Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia.

Palich R, Veyri M, Valantin MA, Marcelin AG, Guihot A, Pourcher V, Jary A, Solas C, Makinson A, Poizot-Martin I, Costagliola D, Spano JP, Katlama C; CancerVIH Study Group.

Clin Infect Dis. 2019 Aug 20. pii: ciz762. doi: 10.1093/cid/ciz762. [Epub ahead of print]

PMID:
31626689
2.

Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort.

Le Guillou A, Pugliese P, Raffi F, Cabie A, Cuzin L, Katlama C, Allavena C, Drame M, Cotte L, Bani-Sadr F; Dat’AIDS Study Group .

Clin Infect Dis. 2019 Aug 17. pii: ciz800. doi: 10.1093/cid/ciz800. [Epub ahead of print]

PMID:
31612225
3.

A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review.

Cox J, Gutner C, Kronfli N, Lawson A, Robbins M, Nientker L, Ostawal A, Barber T, Croce D, Hardy D, Jessen H, Katlama C, Mallolas J, Rizzardini G, Alcorn K, Wohlfeiler M, Le Fevre E.

PLoS One. 2019 Aug 19;14(8):e0220060. doi: 10.1371/journal.pone.0220060. eCollection 2019.

4.

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

Valantin MA, Durand L, Wirden M, Assoumou L, Caby F, Soulié C, Nguyen TT, Tubiana R, Kirstetter M, Junot H, Marcelin AG, Peytavin G, Tilleul P, Katlama C.

J Antimicrob Chemother. 2019 Sep 1;74(9):2716-2722. doi: 10.1093/jac/dkz255.

PMID:
31273376
5.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D; members of the ANRS 163 ETRAL study .

J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. doi: 10.1093/jac/dkz224.

PMID:
31269208
6.

Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.

Spano JP, Veyri M, Gobert A, Guihot A, Perré P, Kerjouan M, Brosseau S, Cloarec N, Montaudié H, Helissey C, Flament T, Gounant V, Lavolé A, Poizot-Martin I, Katlama C.

AIDS. 2019 Sep 1;33(11):F13-F19. doi: 10.1097/QAD.0000000000002298.

PMID:
31259762
7.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial.

Vieillard V, Combadière B, Tubiana R, Launay O, Pialoux G, Cotte L, Girard PM, Simon A, Dudoit Y, Reynes J, Rockstroh J, Garcia F, Gatell J, Devidas A, Yazdanpanah Y, Weiss L, Fätkenheuer G, Autran B, Joyeux D, Gharakhanian S, Debré P, Katlama C.

NPJ Vaccines. 2019 Jun 3;4:25. doi: 10.1038/s41541-019-0117-5. eCollection 2019. Erratum in: NPJ Vaccines. 2019 Aug 13;4:36.

8.

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

Lambert-Niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard JL, Palich R, Agher R, Valantin MA, Calvez V, Katlama C, Girard PM, Marcelin AG, Morand-Joubert L.

Open Forum Infect Dis. 2019 Apr 10;6(5):ofz177. doi: 10.1093/ofid/ofz177. eCollection 2019 May.

9.

Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals.

Januel E, Godin O, Moulignier A, Lescure FX, Savatovsky J, Lamirel C, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D, Assoumou L; Microvascular Brain Retina And Kidney (MicroBREAK) Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):547-551. doi: 10.1097/QAI.0000000000002084.

PMID:
31107300
10.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E.

J Antimicrob Chemother. 2019 Jul 1;74(7):2019-2023. doi: 10.1093/jac/dkz151.

PMID:
31050739
11.

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.

Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L, Piroth L, Bouchaud O, Katlama C, Morlat P, Lascoux-Combe C, Gervais A, Naqvi A, Rosenthal E, Garipuy D, Barange K, Esterle L, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1387-1396. doi: 10.1097/MEG.0000000000001408.

PMID:
31033848
12.

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery.

Assoumou L, Thormann F, Soulié C, Caby F, Dudoit Y, Marcelin AG, Goudot P, Blanc C, Coriat P, Katlama C, Costagliola D, Pourcher V.

HIV Med. 2019 May;20(5):353-358. doi: 10.1111/hiv.12732. Epub 2019 Mar 29.

PMID:
30924598
13.

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.

Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, Katlama C, Raffi F, Leport C, Capeau J; ANRS CO, APROCO-COPILOTE Cohort study group.

Diabetes Metab. 2019 Mar 9. pii: S1262-3636(19)30055-2. doi: 10.1016/j.diabet.2019.02.008. [Epub ahead of print]

PMID:
30862472
14.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.

Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group.

Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.

PMID:
30815916
15.

High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients.

Todesco E, Day N, Amiel C, Elaerts S, Schneider V, Roudière L, Hué S, Liotier JY, Bottero J, L'Yavanc T, Ohayon M, Gosset D, Thibault V, Surgers L, Chas J, Akhavan S, Velter A, Katlama C, Kreplak G, Marcelin AG, Valantin MA.

Int J Antimicrob Agents. 2019 May;53(5):678-681. doi: 10.1016/j.ijantimicag.2019.02.002. Epub 2019 Feb 8.

16.

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.

Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C.

J Antimicrob Chemother. 2019 May 1;74(5):1389-1394. doi: 10.1093/jac/dkz004.

PMID:
30690509
17.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR; NEAT001/ANRS143 Trial Study Group.

PLoS One. 2019 Jan 28;14(1):e0209911. doi: 10.1371/journal.pone.0209911. eCollection 2019.

18.

Caution is needed in interpreting HIV transmission chains by ultradeep sequencing.

Todesco E, Wirden M, Calin R, Simon A, Sayon S, Barin F, Katlama C, Calvez V, Marcelin AG, Hué S.

AIDS. 2019 Mar 15;33(4):691-699. doi: 10.1097/QAD.0000000000002105.

PMID:
30585843
19.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
20.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

21.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.

Cuzin L, Pugliese P, Katlama C, Bani-Sadr F, Ferry T, Rey D, Lourenco J, Bregigeon S, Allavena C, Reynes J, Cabié A; Dat’AIDS Study Group.

J Antimicrob Chemother. 2019 Mar 1;74(3):754-760. doi: 10.1093/jac/dky497.

PMID:
30534993
22.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.

23.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group.

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
24.

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Lê MP, Chaix ML, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS-165 DARULIGHT study group.

Br J Clin Pharmacol. 2019 Jan;85(1):277-280. doi: 10.1111/bcp.13796. Epub 2018 Nov 12. No abstract available.

PMID:
30421447
25.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F; Dat’AIDS study group.

PLoS One. 2018 Sep 21;13(9):e0203895. doi: 10.1371/journal.pone.0203895. eCollection 2018.

26.

HIV.

Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C.

Lancet. 2018 Aug 25;392(10148):685-697. doi: 10.1016/S0140-6736(18)31311-4. Epub 2018 Jul 23. Review.

PMID:
30049419
27.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
28.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193.

PMID:
29905808
29.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.

Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG.

J Antimicrob Chemother. 2018 Sep 1;73(9):2485-2492. doi: 10.1093/jac/dky198.

PMID:
29873733
30.

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).

Molina JM, Gallien S, Chaix ML, El Abbassi EM, Madelaine I, Katlama C, Valin N, Delobel P, Desseaux K, Peytavin G, Saillard J, Raffi F, Chevret S; ANRS 165 Darulight Study Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2129-2136. doi: 10.1093/jac/dky181.

PMID:
29860402
31.

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.

Nouchi A, Nguyen T, Valantin MA, Simon A, Sayon S, Agher R, Calvez V, Katlama C, Marcelin AG, Soulie C.

J Antimicrob Chemother. 2018 Aug 1;73(8):2141-2146. doi: 10.1093/jac/dky130.

PMID:
29846589
32.

An anti-NMDA receptor encephalitis mimicking an HIV encephalitis.

Haneche F, Demeret S, Psimaras D, Katlama C, Pourcher V.

Clin Immunol. 2018 Aug;193:10-11. doi: 10.1016/j.clim.2018.05.003. Epub 2018 May 14.

PMID:
29772276
33.

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.

Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L.

Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382.

PMID:
29767684
34.

Plasma cystatin C as a marker for estimated glomerular filtration rate assessment in HIV-1-infected patients treated with dolutegravir-based ART.

Palich R, Tubiana R, Abdi B, Mestari F, Guiguet M, Imbert-Bismut F, Katlama C, Bonnefont-Rousselot D, Isnard-Bagnis C.

J Antimicrob Chemother. 2018 Jul 1;73(7):1935-1939. doi: 10.1093/jac/dky112.

PMID:
29688533
35.

Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases.

Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, Lambert-Niclot S, Amiel C, Canestri A, Mirand A, Gault E, Vabret A, Valantin MA, Katlama C, Calvez V, Dupin N, Spano JP, Marcelin AG.

J Clin Microbiol. 2018 May 25;56(6). pii: e00569-18. doi: 10.1128/JCM.00569-18. Print 2018 Jun. No abstract available.

36.

Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).

Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, De Truchis P, Katlama C, Martin-Blondel G, Henn A, Revest M, Robineau O, Khuong-Josses MA, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J, Costagliola D; French Hospital Database on HIV (ANRS-C4).

Clin Infect Dis. 2018 Jul 2;67(2):275-282. doi: 10.1093/cid/ciy074.

PMID:
29635465
37.

Dolutegravir resistance mutations: lessons from monotherapy studies.

Blanco JL, Marcelin AG, Katlama C, Martinez E.

Curr Opin Infect Dis. 2018 Jun;31(3):237-245. doi: 10.1097/QCO.0000000000000453. Review.

PMID:
29634660
38.

[HIV and cancer : What's new in 2017?]

Gobert A, Veyri M, Poizot-Martin I, Lavolé A, Solas C, Paliche R, Katlama C, Costagliola D, Spano JP.

Bull Cancer. 2018 Mar;105(3):256-262. doi: 10.1016/j.bulcan.2018.02.002. Epub 2018 Mar 13. Review. French.

PMID:
29548534
39.

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.

Arenas-Pinto A, Grund B, Sharma S, Martinez E, Cummins N, Fox J, Klingman KL, Sedlacek D, Collins S, Flynn PM, Chasanov WM, Kedem E, Katlama C, Sierra-Madero J, Afonso C, Brouwers P, Cooper DA; INSIGHT START study group.

Clin Infect Dis. 2018 Jul 18;67(3):420-429. doi: 10.1093/cid/ciy051.

40.

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.

Malet I, Ambrosio FA, Subra F, Herrmann B, Leh H, Bouger MC, Artese A, Katlama C, Talarico C, Romeo I, Alcaro S, Costa G, Deprez E, Calvez V, Marcelin AG, Delelis O.

J Antimicrob Chemother. 2018 May 1;73(5):1158-1166. doi: 10.1093/jac/dkx529.

PMID:
29373677
41.

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G; ANRS 144 Inter-ACTIV study group.

Lancet HIV. 2018 Mar;5(3):e126-e135. doi: 10.1016/S2352-3018(18)30002-X. Epub 2018 Jan 9.

PMID:
29329763
42.

Do CCR5 antagonists improve the overall survival of patients with AIDS-related progressive multifocal leucoencephalopathy?

Januel E, Martin-Blondel G, Lamirel C, Picard H, Pialoux G, Katlama C, Cochereau I, Lescure FX, Moulignier A.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1125-1126. doi: 10.1136/jnnp-2017-317203. Epub 2018 Jan 5. No abstract available.

PMID:
29305436
43.

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals.

Moulignier A, Savatovsky J, Assoumou L, Lescure FX, Lamirel C, Godin O, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Abrivard M, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D; Microvascular Brain Retina and Kidney (MicroBREAK) Study Group.

Clin Infect Dis. 2018 May 17;66(11):1762-1769. doi: 10.1093/cid/cix1075.

PMID:
29244126
44.

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.

Seang S, Schneider L, Nguyen T, Lê MP, Soulie C, Calin R, Caby F, Valantin MA, Tubiana R, Assoumou L, Marcelin AG, Peytavin G, Katlama C.

J Antimicrob Chemother. 2018 Feb 1;73(2):490-493. doi: 10.1093/jac/dkx417.

PMID:
29216346
45.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.

de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group.

J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434.

PMID:
29186458
46.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3502. doi: 10.1093/jac/dkx383. No abstract available.

PMID:
29121210
47.

Impact of lean mass and bone density on glomerular filtration rate estimation in people living with HIV/AIDS.

Isnard Bagnis C, Pieroni L, Inaoui R, Maksud P, Lallauret S, Valantin MA, Tubiana R, Katlama C, Deray G, Courbebaisse M, Tourret J, Tezenas du Montcel S.

PLoS One. 2017 Nov 2;12(11):e0186410. doi: 10.1371/journal.pone.0186410. eCollection 2017.

48.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434. doi: 10.1093/jac/dkx300. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3502.

PMID:
28961719
49.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
50.

Ageing with HIV: do comorbidities and polymedication drive treatment optimization?

Cuzin L, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C, Rey D, Poizot-Martin I, Chirouze C, Bani-Sadr F, Cabié A; Dat'AIDS Study Group.

HIV Med. 2017 Jul;18(6):395-401. doi: 10.1111/hiv.12441. Epub 2016 Oct 7.

Supplemental Content

Loading ...
Support Center